TCM
CLBT icon

Tybourne Capital Management’s Cellebrite CLBT Stock Holding History

Tybourne Capital Management’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-115,615
Closed -$1.95M – 34
2024
Q3 		$1.95M Buy
+115,615
New +$1.72M 0.55% 23

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AE
Axon Enterprise Scottsdale, Arizona $18.1M AUM 29.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
CC
Crosslink Capital Menlo Park, California $1.02B AUM 9.21% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return

Tybourne Capital Management's CLBT Position: Q4 2024 in Review

Tybourne Capital Management sold out of Cellebrite (CLBT) in Q4 2024, closing a stake of 115,615 shares — an estimated $1.95M sold.

Tybourne Capital Management first reported a position in CLBT in Q3 2024 and held it in 1 quarter. The position peaked at $1.95M in Q3 2024. 191 funds tracked by Wall St. Rank hold CLBT as of Q4 2024.

  • Tybourne Capital Management reported no remaining Cellebrite position as of Q4 2024 after selling out during the quarter.
  • Tybourne Capital Management sold 115,615 Cellebrite shares in Q4 2024, an estimated $1.95M.
  • Tybourne Capital Management first reported a position in Cellebrite in Q3 2024 and held it in 1 quarter.
  • Tybourne Capital Management's Cellebrite position peaked at $1.95M in Q3 2024.
  • 191 funds tracked by Wall St. Rank held Cellebrite as of Q4 2024.

Based on Tybourne Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.